The exact molecular mechanisms by which PTGFRN influences cancer progression are still unknown. Our laboratory set out to investigate how PTGFRN knockdown affected the expression of other proteins. We also carried out co-immunoprecipitation experiments using a monoclonal anti-PTGFRN antibody. We employed mass spectrometry-based proteomics for both experiments to identify proteins that were associated with PTGFRN.